Last reviewed · How we verify
CinnaTropin®
CinnaTropin® is a recombinant human growth hormone that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.
CinnaTropin® is a recombinant human growth hormone that binds to growth hormone receptors to promote growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature in children.
At a glance
| Generic name | CinnaTropin® |
|---|---|
| Also known as | recombinant human growth hormone (CinnaTropin®) |
| Sponsor | Cinnagen |
| Drug class | Recombinant human growth hormone (somatropin) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
CinnaTropin® is a somatropin (recombinant human growth hormone) product that mimics endogenous GH by activating growth hormone receptors on target tissues. This stimulates insulin-like growth factor-1 (IGF-1) production, increases protein synthesis, promotes lipolysis, and enhances linear growth in children and metabolic effects in adults.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature in children
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Carpal tunnel syndrome
- Arthralgia
- Fluid retention
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |